"Eli Lilly has built one of the most remarkable growth stories in modern pharmaceutical history through its GLP-1 franchises, with Mounjaro and Zepbound conquering the weight-loss market and giving Lilly roughly a 60% share of the weight-loss opportunity."
"The consensus one-year price target sits at $1,209.21, implying significant upside from the current price of $935.58, supported by 24 Buy ratings, 6 Hold, and just 1 Sell."
"Lilly currently trades at a forward multiple relative to the midpoint of its 2026 EPS guidance, and hitting $1,120 would imply a meaningfully higher forward multiple on 2026 earnings."
"CEO David Ricks confirmed a new collaboration with NVIDIA to open a co-innovation AI lab, combining Lilly's scientific expertise with NVIDIA's technology to accelerate drug discovery."
Eli Lilly has achieved remarkable growth through its GLP-1 franchises, Mounjaro and Zepbound, capturing a 60% share of the weight-loss market. Projected revenue for 2025 is $65.18 billion, a 44.7% increase year-over-year. Analysts predict a one-year price target of $1,209.21, indicating substantial upside from the current price. Lilly's 2026 revenue guidance is between $80 billion and $83 billion, with EPS guidance of $33.50 to $35.00. Key catalysts include Orforglipron FDA approval and a collaboration with NVIDIA for AI drug discovery.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]